Cet anticorps Lapin Monoclonal détecte spécifiquement CRABP2 dans WB, IHC, IF, ICC et FACS. Il présente une réactivité avec des échantillons de Humain, Souris et Rat.
CRABP2
Reactivité: Humain
WB, IF
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
Optimal dilution of the CRABP2 antibody should be determined by the researcher.
Restrictions
For Research Use only
Format
Liquid
Buffer
Rabbit IgG in phosphate buffered saline, pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol, 0.4-0.5 mg/mL BSA
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
-20 °C
Stockage commentaire
Store the CRABP2 antibody at -20oC.
Antigène
CRABP2
(Cellular Retinoic Acid Binding Protein 2 (CRABP2))
Autre désignation
CRABP2
Sujet
CRABP2 antibody detects cellular retinoic acid-binding protein 2, encoded by the CRABP2 gene. Alternate names include CRABP-II, cellular retinoic acid-binding protein type II, and RA-binding protein 2. CRABP2 is a cytoplasmic protein that binds retinoic acid with high affinity, delivering it to the nucleus to interact with retinoic acid receptors (RARs). This shuttling mechanism ensures efficient retinoic acid signaling, which regulates cell differentiation, growth, and development. Structurally, CRABP2 belongs to the fatty acid-binding protein family, characterized by a beta-barrel fold that binds hydrophobic ligands.
CRABP2 antibody is widely applied in developmental biology, cancer research, and dermatology. Retinoic acid is essential for embryonic patterning, limb development, and organogenesis, and CRABP2 ensures delivery of ligand to nuclear receptors. In skin, CRABP2 regulates keratinocyte differentiation and retinoid responses, linking it to dermatological therapies. In cancer biology, CRABP2 expression modulates sensitivity to retinoids, influencing proliferation and apoptosis.
Applications of CRABP2 antibody include western blotting, immunohistochemistry, immunofluorescence, and ELISA. Western blotting detects CRABP2 protein in cell and tissue lysates, immunohistochemistry maps expression in embryonic and tumor tissues, and immunofluorescence highlights cytoplasmic and nuclear localization. These methods support research into retinoid signaling in diverse contexts.
Dysregulation of CRABP2 is linked to developmental abnormalities, cancer progression, and skin disease. Overexpression promotes retinoid sensitivity in some cancers, while downregulation confers resistance. By applying CRABP2 antibody, researchers can study how retinoid signaling contributes to disease and therapy response.
CRABP2 interacts with nuclear RARs, cytoplasmic enzymes, and signaling molecules. This positions it as a central mediator of vitamin A biology. NSJ Bioreagents provides CRABP2 antibody with validated specificity, supporting accurate detection in studies of development, cancer, and dermatology.